Skip to main content

Table 1 Demographic and clinical characteristics of the patients treated with the combination of azithromycin and atovaquone

From: Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone

Characteristic

All (N = 40)

Admitted to ICU (n = 11)

Not admitted to ICU (n = 29)

P value

Age

64 (47–81)

60 (47–73)

66 (52–80)

0.44

Gender

 Male

26 (65)

8 (73)

18 (62)

0.58

 Female

14 (35)

3 (27)

11 (38)

0.72

Race

 White

24 (60)

8 (73)

16 (55)

0.39

 African American

0

0

0

 

 Hispanic

8 (20)

3 (27)

5 (17)

0.74

 Asian

1 (3)

0 (0)

1 (3)

 

 Declined

2 (5)

0 (0)

2 (7)

 

 Other

5 (13)

0 (0)

5 (17)

 

Comorbidities

 Hypertension

17 (43)

6 (55)

11 (38)

0.49

 Diabetes mellitus

7 (18)

6 (55)

1 (3)

0.33

 Heart disease (CHF/CAD/Arrhythmias)

9 (23)

3 (27)

6 (21)

0.84

 Blood disease

2 (5)

0

2 (7)

 

 Cancer

4 (10)

0

4 (14)

 

 CKD

3 (8)

1 (9)

2 (7)

 

 COPD/asthma

6 (15)

2 (18)

4 (14)

0.89

 Liver disease

2 (5)

2 (18)

0

 

 Autoimmune disease

3 (8)

0

3 (10)

 

 HIV

1 (3)

0

1 (3)

 

 Splenectomy

5 (13)

1 (9)

4 (14)

 

 Days in hospital

5 (1–9)

6 (2–11)

5 (1–11)

0.55

Clinical/lab characteristics

 SAPS II score (points)

20 (14–26)

21 (10–32)

20 (14–26)

0.69

 Temperature on admission (C)

38.5 (37.2–39.8)

37.2 (35.6–38.8)

38.6 (37.6–39.8)

0.03

 Peak parasitemia (%)

1.3 (2.5–5.1)

5.0 (1.5–11.5)

1.1 (1.1–3.3)

0.003

 Days of parasitemia (number)

4 (1.75–6.25)

4.5 (1.5–7.5)

4 (1.2–6.8)

0.70

 Hemoglobin (g/dL)

10.7 (8.4–13.0)

10.0 (7.9–12.2)

11.1 (8.7–13.5)

0.33

 Platelets (×103/μL)

74 (8.3–138.8)

64 (1.8–128.8)

74 (8.0–139.0)

0.66

 AST (U/L)

79 (13–146)

87 (29–146)

72 (2–142)

0.52

 ALT (U/L)

59 (4–114)

63 (1–125)

46 (4–96)

0.33

 Total bilirubin (mg/dL)

1.3 (0.8–1.8)

1.5 (0.4–2.6)

1.3 (0.8–1.8)

0.40

 LDH (U/L)

605 (231–979)

719 (282–1157)

535 (208–862)

0.12

 Haptoglobin (mg/dL)

7.4 (6.7–8.1)

7.2 (1.5–15.9)

7.4 (7.1–7.7)

0.66

Exchange transfusions

 No

34 (85)

6 (55)

28 (97)

0.002

 Yes (one)

6 (15)

5 (45)

1 (3)

0.42

Outcome

 Improved and discharged

39 (98)

11 (100)

28 (97)

 

 Died

1 (2)

0

1 (3)

 
  1. Data are presented as median (IQR) or No. (%)